Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0393754 (
HSA
)
2,996
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CD22
is a B cell-restricted surface molecule which may play an important role in interactions between B cells and other cells and in regulating signals through the B cell receptor (BCR) complex. Here we have examined whether the mouse is a suitable in vivo model for studying
CD22
functions. In primary and secondary lymphoid organs of adult mice
CD22
is on all mature B cells, including resting IgM+IgD+ B cells, IgG+
HSA
(lo) memory B cells, syndecan+ plasma cells and CD5+ B cells, but it is not on immature IgM+IgD- B cells. Biochemical analysis revealed that murine
CD22
is associated with the IgM receptor in some, but not all, CD22+ B leukemic and lymphoma cell lines; as with human
CD22
, murine
CD22
is rapidly phosphorylated on tyrosine after ligation of the BCR. In the
CD22
- murine pro-B cell line, FEMCL,
CD22
expression was inducible by treatment with phorbol 12-myristate 13-acetate. A genomic fragment of the cd22b allele containing 1.3 kb 5' of exon 1 was sequenced in order to identify potential DNA regulatory elements in the
CD22
promoter region. Consensus sequences for transcription factor binding sites including PU.1, AP-1, AP-2, C/EBP and SP-1 were present, but no classical TATA elements or initiator motifs were evident at relevant positions. The 1.3-kb promoter fragment 5' of exon 1 was sufficient for directing basal promoter activity in B and T cells. There was no significant sequence similarity between the murine and human cd22 gene promoters, although both contain repetitive elements and Sp-1 and AP1 binding sites. Thus, murine
CD22
shares a number of features with human
CD22
and the mouse provides a suitable model system for elucidating the function of
CD22
in vivo.
...
PMID:Characterization of the expression and gene promoter of CD22 in murine B cells. 897 19
Understanding the molecular mechanisms through which
CD22
regulates B lymphocyte homeostasis, signal transduction, and tolerance is critical to defining normal B cell function and understanding the role of
CD22
in autoimmunity. Therefore,
CD22
function was examined in vivo and in vitro using B cells from
CD22
-deficient (
CD22
(-/-)) mice. Backcrossing of founder
CD22
(-/-) mice onto the C57BL/6 (B6) genetic background from a B6/129 mixed background resulted in a dramatically reduced B cell proliferative response following IgM ligation, characterized by a paucity of lymphoblasts and augmented apoptosis. Also, the phenotype of splenic B6
CD22
(-/-) B cells was uniquely
HSA
(high) and IgD(low)/CD21(low) with intermediate levels of CD5 expression, although the percentages of mature and transitional B cells were normal. That B6
CD22
(-/-) B cells predominantly underwent apoptosis following IgM ligation correlated with this unique tolerant phenotype, as well as defective induction of the c-Myc:Cullin 1 (CUL1) ubiquitin ligase pathway that is necessary for progression to the S phase of cell cycle. CD40 ligation compensated for
CD22
deficiency by restoring lymphoblast development, proliferation, c-Myc and CUL1 expression, and protein ubiquitination/degradation in IgM-stimulated B6
CD22
(-/-) B cell cultures. Thereby, this study expands our current understanding of the complex role of
CD22
during B cell homeostasis and Ag responsiveness, and reveals that the impact of
CD22
deficiency is dictated by the genetic background on which it is rendered. Moreover, this study defines
CD22
and CD40 as the first examples of lymphocyte coreceptors that influence induction of the c-Myc:CUL1 ubiquitin ligase pathway.
...
PMID:Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. 1476 75